S-adenosylhomocysteine (SAH) and homocysteine are produced when SAM donates its methyl group
So it's very benign, there's no risk, and it certainly helps a lot of our patients
Heres what you need to know: Target Tissue: Works specifically on adipose tissue without systemic growth hormone effects or muscle tissue impact Mechanism: Activates beta-3 adrenergic receptors on fat cell membranes, triggering intracellular fat-burning cascades Primary Action: Stimulates hormone-sensitive lipase to break down stored triglycerides into free fatty acids for energy utilization Secondary Action: Inhibits lipogenic enzymes that convert excess calories into stored fat Regional Selectivity: Particularly effective on visceral (deep abdominal) and subcutaneous fat deposits with high beta-3 receptor concentration Preservation Effect: Targets fat tissue selectively without promoting muscle protein breakdown or affecting lean tissue Unique Advantage: Does not bind to growth hormone receptors, avoiding effects on IGF-1, glucose metabolism, or insulin sensitivity Research Validation: Clinical trials with 900+ participants confirmed selective fat metabolism effects with excellent safety profile The following guide provides detailed analysis of how AOD-9604 targets fat cells, from receptor binding to metabolic outcomes
In the three human studies completed, the safety profile has been promising
It is not a list of FDA-approved medications, proven treatments, recommended therapies, or products that any pharmacy may sell without restriction
Subcutaneous (SubQ) Needles Subcutaneous needles are suitable for injections into the fatty tissue just beneath the skin
